May 15, 2021
For immediate post-MI patients, sacubitril/valsartan (Entresto; Novartis) does not significantly decrease the risk of heart failure (HF) or CV death compared with an ACE inhibitor, the PARADISE-MI trial shows.
sacubitril/valsartan is superior to an ACE inhibitor in patients who have symptomatic HF with reduced ejection fraction when it comes to reducing both HF events and total mortality, PARADISE-MI fell short by missing its primary endpoint of a 15% reduction in events needed to demonstrate superiority of the angiotensin receptor neprilysin inhibitor (ARNI) over an ACE inhibitor, ramipril, in this acute MI population. Nevertheless, there was a 10% reduction in the sacubitril/valsartan group and positive reports of reduced events from investigators who participated in the large multinational trial.
A simple surgery can save patients with irregular heart beats from often-fatal strokes, according to a large international study led by researchers at McMaster University in Hamilton, Ontario. There is an unused, finger-like appendage in the heart which can trap blood and increase the risk of clots. Removing this left atrial appendage was found to…
May 15, 2021
Emergent CABG surgery has seen waning use over the past few decades among patients hospitalized for acute MI in the United States, a trend not likely to come as a surprise to cardiologists watching PCI’s ascendance. But nationwide data also show that even as the patients targeted for CABG therapy have grown sicker and higher-risk, their in-hospital mortality rates have decreased.
The data, encompassing more than 11 million acute MI admissions from 2000 to 2017, were released today during the virtual American College of Cardiology (ACC) 2021 Scientific Session and simultaneously published online in the
Journal of the American Heart Association.
“There has been a near 90% reduction in the need for emergency CABG for acute myocardial infarction [over the years], primary due to the emergence of percutaneous coronary interventions and the associated outcomes,” Sri Harsha Patlolla, MBBS (Mayo Clinic, Rochester, MN), said when presenting the ACC abstract. Yet there